William Wilson Troutman - 07 Feb 2022 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: CFO and Secretary
Issuer ticker: ETON
Reported as of: 07 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 15:32:31 UTC
Prior SEC filing: 20 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ W.Wilson Troutman

Key filing fact

William Wilson Troutman filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 28 Feb 2022.

Key facts

This page summarizes William Wilson Troutman's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2022, 15:32.

Change

Previous filing in this sequence was filed on 20 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %: +2.3%
Price: $0.000000
Shares after: 671,200
Date: 07 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $3.78
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2026.